Loading…
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. First Tracks Biotherapeutics, Inc. operates as a subsidiary of AnaptysBio, Inc.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2024
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2024 | $0M | $-179M | $-164M | $-126M | -41.8% | - | - |
| 2023 | $0M | $-116M | $-106M | $-94M | -25.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2023 | 2024 |
|---|---|---|
| Total Revenue | 0 | 0 |
| Operating Expense | 118.46 | 181.10 |
| Operating Income | -118.46 | -181.10 |
| EBITDA | -116.08 | -178.70 |
| EBIT | -118.46 | -181.10 |
| Pretax Income | -106.15 | -163.71 |
| Net Income | -106.15 | -163.71 |
| Net Income Common Stockholders | -106.15 | -163.71 |
| Total Expenses | 118.46 | 181.10 |
| Interest Income | 12.31 | 17.38 |
| Research And Development | 97.59 | 152.34 |
| Selling General And Administration | 20.87 | 28.76 |
| Normalized EBITDA | -116.08 | -178.70 |
| Normalized Income | -106.15 | -163.71 |
| Basic EPS | -3.05 | 0 |
| Diluted EPS | -3.05 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -106.15 | -163.71 |
| Reconciled Depreciation | 2.38 | 2.40 |
| Net Interest Income | 12.31 | 17.38 |
| Net Income From Continuing And Discontinued Operation | -106.15 | -163.71 |
| Total Operating Income As Reported | -118.46 | -181.10 |
| Diluted Average Shares | 34.75 | 0 |
| Basic Average Shares | 34.75 | 0 |
| Diluted NI Availto Com Stockholders | -106.15 | -163.71 |
| Net Income Including Noncontrolling Interests | -106.15 | -163.71 |
| Net Income Continuous Operations | -106.15 | -163.71 |
| Other Income Expense | 0 | 0.01 |
| Other Non Operating Income Expenses | 0 | 0.01 |
| Net Non Operating Interest Income Expense | 12.31 | 17.38 |
| Interest Income Non Operating | 12.31 | 17.38 |
| General And Administrative Expense | 20.87 | 28.76 |
| Other Gand A | 20.87 | 28.76 |
| Operating Revenue | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| First Tracks Biotherapeutics, Inc.this co. | TRAX | $821M | - | - | -41.8% | - |
| EVMN | EVMN | $859M | - | 3.66 | -33.5% | -8.93 |
| Theravance Biopharma, Inc. | TBPH | $859M | 8.09 | 2.87 | 35.7% | -296.42 |
| MannKind Corporation | MNKD | $849M | 137.50 | -16.57 | -11.5% | 19.49 |
| Omada Health, Inc. | OMDA | $841M |
| - |
| 3.60 |
| -5.6% |
| -94.35 |
| OPKO Health, Inc. | OPK | $838M | - | 0.66 | -17.8% | -7.47 |
| MeiraGTx Holdings plc | MGTX | $828M | - | -126.06 | 1971.4% | -8.05 |
| Arbutus Biopharma Corporation | ABUS | $813M | - | 10.38 | -43.7% | -26.98 |
| Cullinan Therapeutics, Inc. | CGEM | $790M | - | 1.89 | -53.8% | -1.67 |
| Peer Median | - | 72.80 | 2.38 | -14.6% | -8.49 | |